Business
Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Achieved YUTREPIA® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarterMore than 3,600 unique prescriptions
About this update from Liquidia Corporation
[{"type":"text","content":"Achieved YUTREPIA® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarterMore than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in June 2025Ended 2025 with $190.7 million in cash and cash equivalents, an increase of $33.2 million from the third quarterRecorded second consecutive quarter of profitability MORRISVILLE, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the full year ended December 31, 2025. The company will also host a webcast at 8:30 a.m. ET on March 5, 2026, to discuss its financial results and provide a corporate update. Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “As we close 2025, we are encouraged by how quickly YUTREPIA® has taken hold in clinical practice, placing it among one of the top specialty drug launches over the past five years across all therapeutic categories. Adoption continues to broaden across PAH and PH-ILD, with increasing depth in treatment centers and more experience transitioning appropriate patients from oral, inhaled and systemic prostacyclin therapies. Having increased profitability in our second full quarter after launch, we will build on this foundation in 2026 from a position of financial strength. We plan to deepen prescriber adoption, grow our sales force, expand YUTREPIA’s clinical evidence through multiple new studies, and advance L606 into pivotal trials, all of which will be funded from operations. We believe YUTREPIA and L606 have the potential to establish a new standard for the use of inhaled prostacyclin as a critical therapeutic modality across serious and progressive cardiopulmonary diseases.” YUTREPIA® Commercial Launch Highlights (as of February 28, 2026) Received more than 3,600 unique patient prescriptions since launchStarted more than 2,900 patients on treatment since launchPrescription-to-start conversion remained strong at or above the 85% level reported in the third quarter of 2025Increased total number of prescribers to approximately 860, more than half of whom have prescribed YUTREPIA to at least 2 patients and 25% have referred 5 or more patients Fourth Qu...